Idrinol, 100 mg/ml 5 ml 5 pcs

Idrinol is a metabolism-improving agent, an analogue of gamma-butyrobetaine. Inhibits gamma-butyrobetaine hydroxinase, inhibits carnitine synthesis and transport of long-chain fatty acids through cell membranes, prevents the accumulation of activated forms of non-oxidized fatty acids in cells – derivatives of acylcarnitine and acylkoenzyme A.

In conditions of ischemia it restores equilibrium of oxygen delivery and consumption in cells, prevents the disruption of ATP transport, while simultaneously activating glycolysis, which proceeds without additional oxygen consumption. As a result of decrease of carnitine concentration, gamma -butyrobetaine is intensively synthesized, which has vasodilatory properties. The mechanism of action determines a variety of its pharmacological effects: increase of work capacity, reduction of symptoms of mental and physical overexertion, activation of tissue and humoral immunity, cardioprotective effect. In acute ischemic myocardial injury it slows down the formation of the necrotic zone and shortens the rehabilitation period.

In case of heart failure it increases myocardial contractility, increases exercise tolerance, reduces the frequency of angina attacks.

In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the focus of ischemia, helps redistribute blood in favor of the ischemic area. It is effective for vascular and dystrophic fundus pathology.

It has a tonic effect on the central nervous system, eliminates the functional disorders of the nervous system in patients with chronic alcoholism in withdrawal syndrome.

Indications

For intravenous administration: in complex therapy of CHD (angina pectoris, myocardial infarction), chronic heart failure, dyshormonal cardiomyopathy; in complex therapy of acute and chronic cerebrovascular disorders (strokes and cerebrovascular failure); reduced work capacity, physical overexertion (incl. athletes).In athletes), postoperative period to accelerate rehabilitation; withdrawal syndrome in chronic alcoholism (in combination with specific alcohol therapy).

For parabulbar injection: acute impairment of blood circulation in the retina, hemophthalmus and retinal hemorrhages of different etiology, central retinal vein thrombosis and its branches, retinopathies of different etiology (including diabetic and hypertensive) – only for parabulbar injection.

Active ingredient

Composition

The solution for parabulbar and intravenous administration.

1 ml contains meldonium 100 mg.

How to take, the dosage

In connection with the possibility of development of excitatory effect it is recommended to use in the morning. The dose is set individually depending on indications and route of administration.

In case of intravenous administration the dose is 0.5-1 g once a day, the duration of treatment depends on the indication.

Parabulbaria is injected 0.5 ml of the solution for injection with the concentration of 500 mg/5 ml for 10 days.

Interaction

When used together, meldonium increases the effect of antianginal agents, some hypotensive drugs, cardiac glycosides.

In concomitant use of meldonium with nitroglycerin, nifedipine, alpha-adrenoblockers, antihypertensive agents and peripheral vasodilators, moderate tachycardia and arterial hypotension may develop (caution is required with these combinations).

Special Instructions

Idrinol is not a first-line drug for acute coronary syndrome.

Idrinol has no effect on the ability to drive and operate machinery:

There are no data on adverse effects of the drug Idrinol on the speed of psychomotor reactions.

Contraindications

Elevated intracranial pressure (including venous outflow disorders, intracranial tumors), pregnancy, lactation (breastfeeding), hypersensitivity to meldonium.

Side effects

Cardiovascular system: rarely – tachycardia, BP changes.

CNS disorders: rarely – psychomotor agitation.

Digestive system: rare – dyspeptic symptoms.

Allergic reactions: rare – skin itching, redness, rash, swelling.

Overdose

Symptoms: decreased BP accompanied by headache, tachycardia, dizziness and general weakness.

Treatment: symptomatic

Similarities